Author: "Sakai-Tagawa, Yuko" / Language: english / Topic: antiviral agents and viral antibodies - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Sakai-Tagawa, Yuko"' showing total 3 results

Start Over Author "Sakai-Tagawa, Yuko" Topic antiviral agents Topic viral antibodies Language english

Author: Emi Takashita, Seiya Yamayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Halfmann, Peter, Wilson, Nancy, Ries, Hunter, Richardson, Alex, Bobholz, Max, Vuyk, William, Maddox, Robert, Baker, David A, Friedrich, Thomas C, O'Connor, David H, Uraki, Ryuta, Ito, Mutsumi, Sakai-Tagawa, Yuko, Adachi, Eisuke, and Saito, Makoto
Subjects: *ANTIVIRAL agents, *VIRAL antibodies, *PHARMACODYNAMICS
Abstract: The article informs about the BA.S subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant has become dominant in most countries around the world. Topics incluyde the amino acid substitutions in the receptorbinding domain of the spike protein, which is the major target for vaccines and therapeutic monoclonal antibodies against SARS-CoV-2; and effectiveness of current vaccines and therapeutic monoclonal antibodies against this subvariant will be decreased.
Published: 2022
Full Text: View/download PDF

Author: Emi Takashita, Selya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Ito, Mutsumi, Uraki, Ryuta, Halfmann, Peter, Watanabe, Shinji, Takeda, Makoto, Hasegawa, Hideki, Imai, Masaki, and Kawaoka, Yoshihiro
Subjects: *IMMUNOGLOBULINS, *ANTIVIRAL agents, *RESEARCH funding, *VIRAL antibodies
Published: 2022
Full Text: View/download PDF

Author: Emi Takashita, Seiya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M, Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, and Kawaoka, Yoshihiro
Subjects: *IMMUNOGLOBULINS, *MONOCLONAL antibodies, *ANTIVIRAL agents, *VIRAL antibodies
Abstract: The article discusses The data from our trial suggest that dulaglutide , if ultimately approved for pediatric use, may offer advantages not only with regard to glycemic control but also with regard to its frequency and method of administration. Weekly administration with a device that does not require reconstitution steps or needle handling and that has shown favorable ease-of-use characteristics in preference studies involving.
Published: 2022
Full Text: View/download PDF

Books, media, physical & digital resources

Searchworks